1
|
Anudjo MNK, Vitale C, Elshami W, Hancock A, Adeleke S, Franklin JM, Akudjedu TN. Reply to Letter to the Editor regarding Anudjo et al. 'Considerations for environmental sustainability in clinical radiology and radiotherapy practice: A systematic literature review and recommendations for a greener practice'. Radiography (Lond) 2024; 30:257. [PMID: 38035442 DOI: 10.1016/j.radi.2023.11.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
|
2
|
Anudjo MNK, Vitale C, Elshami W, Hancock A, Adeleke S, Franklin JM, Akudjedu TN. Considerations for environmental sustainability in clinical radiology and radiotherapy practice: A systematic literature review and recommendations for a greener practice. Radiography (Lond) 2023; 29:1077-1092. [PMID: 37757675 DOI: 10.1016/j.radi.2023.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 09/01/2023] [Accepted: 09/11/2023] [Indexed: 09/29/2023]
Abstract
INTRODUCTION Environmental sustainability (ES) in healthcare is an important current challenge in the wider context of reducing the environmental impacts of human activity. Identifying key routes to making clinical radiology and radiotherapy (CRR) practice more environmentally sustainable will provide a framework for delivering greener clinical services. This study sought to explore and integrate current evidence regarding ES in CRR departments, to provide a comprehensive guide for greener practice, education, and research. METHODS A systematic literature search and review of studies of diverse evidence including qualitative, quantitative, and mixed methods approach was completed across six databases. The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines and the Quality Assessment Tool for Studies with Diverse Designs (QATSDD) was used to assess the included studies. A result-based convergent data synthesis approach was employed to integrate the study findings. RESULTS A total of 162 articles were identified. After applying a predefined exclusion criterion, fourteen articles were eligible. Three themes emerged as potentially important areas of CRR practice that contribute to environmental footprint: energy consumption and data storage practices; usage of clinical consumables and waste management practices; and CRR activities related to staff and patient travel. CONCLUSIONS Key components of CRR practice that influence environmental impact were identified, which could serve as a framework for exploring greener practice interventions. Widening the scope of research, education and awareness is imperative to providing a holistic appreciation of the environmental burden of healthcare. IMPLICATIONS FOR PRACTICE Encouraging eco-friendly travelling options, leveraging artificial Intelligence (AI) and CRR specific policies to optimise utilisation of resources such as energy and radiopharmaceuticals are recommended for a greener practice.
Collapse
|
3
|
Ciaglia E, Montella F, Lopardo V, Esposito RM, Guarracino F, Spinetti G, Maciag AA, Ciccarelli M, Vitale C, Pellegrino SG, Polverino B, Izzo C, Vecchione C, Puca AA. Autoantibodies against the cardiovascular protective BPIFB4 in hospitalized patients with COVID-19. Eur Heart J 2022. [PMCID: PMC9619705 DOI: 10.1093/eurheartj/ehac544.2936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Background/Introduction The bactericidal/permeability-increasing fold-containing family-B-member-4 (BPIFB4) serves as a biomarker of healthy aging [1,2] and displays prognostic relevance in vascular pathology [3–5]. We recently described a drop in plasma BPIFB4 level in patients with severe COVID-19 compared to low-grade disease patients [6]. Purpose As COVID-19 is associated with autoimmune features, we developed the methods for determination of Anti-BPIFB4 IgG (autoAbs) and then characterized their neutralizing activity in COVID-19 patients. Methods A sandwich ELISA-based colorimetric assay followed by immunoblot analysis detected the presence of autoAbs against BPIFB4 in 60 hospitalized COVID-19 patients and in 30 healthy volunteers. Compared to the healthy controls, the optical density (OD) level of autoAbs in COVID-19 showed considerable variability distributing over a range between 0.13 and 0.85. We thus divided the patients into two groups, one with OD >0,29 and the other one with a OD >0,29, where 0,29 represents the OD mean value of autoAbs against BPIFB4 in physiological conditions. Results Since patients with higher OD are mainly those who spend in average a higher number of days in hospital, we stratified the patients according to the Length of Stay (LoS) in hospital (Figure 1), and found a trend towards a positive correlation between AutoAbs OD level and length of hospitalization within COVID-19 patients. When present, autoAbs exclusively target the WT-BPIFB4 autoantigens and neglect the recognition of the Longevity-associated-variant-(LAV) of the BPIFB4 gene known for its therapeutic efficacy in cardiomyopathy, atherosclerosis (4), diabetes (6) and platelets' reactivity. As expected, the pre-treatment of human PrP with the recombinant rhLAV-BPIFB4 reduces platelets' aggregation in response to ADP and collagen in COVID-19 patients in vitro. On the other hand, at functional level, the well established LAV-BPIFB4-regulated M2 macrophage polarization (4,7), is neutralized in presence of anti-BPIFB4 autoAbs-enriched plasma. Conclusion We conclude that a significant proportion of hospitalized COVID-19 patients displays BPIFB4-AutoAbs which are positively correlated with the Length of Stay (LoS) in hospital. In future, it will be of utmost importance to clarify if the 4 missense SNPs which distinguish LAV-BPIFB4 gene from its WT-counterpart, are instrumental to prevent the self-tolerance brake-down and the potential development of specific antibodies against endogenous cardiovascular protectors. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Cariplo Foundation (n.2016-0874) to AAP and CV; Ministry of Health (RF-2016-02364864) to AAP and CV
Collapse
|
4
|
Mauro FR, Giannarelli D, Galluzzo C, Visentin A, Frustaci AM, Sportoletti P, Vitale C, Reda G, Gentile M, Levato L, Murru R, Armiento D, Ielo C, Maglione R, Crisanti E, Cipiciani A, Mattiello V, Gianfelici V, Barabino L, Amici R, Coscia M, Tedeschi A, Trentin L, Baroncelli S. P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845524.05971.e8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Cuccia F, Mazzola R, Pastorello E, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Vitale C, Attinà G, Ruggieri R, Alongi F. PO-1463 SBRT for over 80years oligometastatic patients: report of feasibility and clinical outcomes. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03427-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Cuccia F, Pastorello E, Vitale C, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Mazzola R, Ceccaroni M, Ruggieri R, Alongi F. PO-1353 SBRT for gynecological oligometastases: mono-institutional report of toxicity and clinical outcomes. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03317-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Nicosia L, Giaj-Levra N, Sicignano G, Cuccia F, Figlia V, Mazzola R, Ricchetti F, Rigo M, Vitale C, Attinà G, De Simone A, Gurrera D, Ruggeri R, Molon G, Alongi F. PO-1452 Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03416-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Nicosia L, Vitale C, Cuccia F, Rigo M, Figlia V, Mazzola R, Giaj-Levra N, Ricchetti F, Ruggeri R, Alongi F. PD-0574 1.5T MR-guided RT versus linac-based VMAT SBRT in localized prostate cancer: a toxicity comparison. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02889-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Cuccia F, Mazzola R, Pastorello E, Ingrosso G, Franzese C, Scorsetti M, Figlia V, Giaj-Levra N, Nicosia L, Rigo M, Ricchetti F, Vitale C, Attinà G, Ruggieri R, Alongi F. PD-0086 PSMA-PET guided stereotactic body radiotherapy for bone oligorecurrent prostate cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02756-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Nicosia L, Vitale C, Cuccia F, Figlia V, Giaj-Levra N, Mazzola R, Ricchetti F, Rigo M, Ruggero R, Cavalleri S, Alongi F. PO-1407 Postoperative hypofractionated RT: toxicity and efficacy in a series of 304 prostate adenocarcinoma. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03371-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Cuccia F, Mazzola R, Sicignano G, Vitale C, Rigo M, Giaj-Levra N, Nicosia L, Figlia V, Ricchetti F, Attinà G, Pastorello E, De Simone A, Gurrera D, Naccarato S, Ruggieri R, Alongi F. Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intra-fraction motion during 1.5 t-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)02741-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
12
|
Cuccia F, Mazzola R, Pastorello E, Rigo M, Giaj-Levra N, Nicosia L, Figlia V, Ricchetti F, Attinà G, Vitale C, De Simone A, Gurrera D, Naccarato S, Sicignano G, Ruggieri R, Alongi F. PSMA-guided SBRT for bone oligometastatic prostate cancer: a monoinstitutional report of preliminary outcomes and toxicity. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)02743-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
13
|
Cuccia F, Nicosia L, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Vitale C, Attinà G, Pastorello E, Corradini S, Ruggieri R, Alongi F. PO-1376 Preliminary mono-institutional report of prostate/prostate bed SBRT re-irradiation. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07827-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Cuccia F, Mazzola R, Figlia V, Rigo M, Nicosia L, Giaj-Levra N, Ricchetti F, Vitale C, Attinà G, Pastorello E, Di Paola G, De Simone A, Gurrera D, Naccarato S, Sicignano G, Ruggieri R, Alongi F. PO-1388 1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07839-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Nicosia L, Vitale C, Cuccia F, Figlia V, Giaj-Levra N, Mazzola R, Ricchetti F, Rigo M, Ruggieri R, Cavalleri S, Alongi F. PO-1353 Postoperative hypofractionated RT for prostate adenocarcinoma: results from a large series. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07804-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Frustaci AM, Tedeschi A, Zinzani PL, Pietrasanta D, Coscia M, Zenz T, Motta M, Gaidano G, Scarfò L, Deodato M, Zamprogna G, Vitale C, Cairoli R, Rossi D, Montillo M. MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.40_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Romano Gargarella L, Facco M, Piazza F, Marchetti M, Coscia M, Laurenti L, Molica S, Pizzolo G, Foà R, Cuneo A, Trentim L. EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.46_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
18
|
Ferronato MJ, Nadal Serrano M, Arenas Lahuerta EJ, Bernadó Morales C, Paolillo G, Martinez-Sabadell Aliguer A, Santalla H, Mascaró M, Vitale C, Fall Y, Arribas J, Facchinetti MM, Curino AC. Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. J Steroid Biochem Mol Biol 2021; 208:105735. [PMID: 32784045 DOI: 10.1016/j.jsbmb.2020.105735] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 07/22/2020] [Accepted: 08/04/2020] [Indexed: 12/24/2022]
Abstract
Despite advances in breast cancer (BC) treatment, its mortality remains high due to intrinsic or acquired resistance to therapy. Several ongoing efforts are being made to develop novel drugs to treat this pathology with the aim to overcome resistance, prolong patient survival and improve their quality of life. We have previously shown that the non-hypercalcemic vitamin D analogues EM1 and UVB1 display antitumor effects in preclinical studies employing conventional cell lines and animal models developed from these cells. In this work, we explored the antitumor effects of EM1 and UVB1 employing BC cells derived from patient-derived xenografts (PDXs), which are a powerful preclinical tool for testing new drugs. We demonstrated that the analogues reduced the viability of HER2-positive and Triple Negative BC-PDXs. Moreover, using an in vitro model of acquired resistance to Trastuzumab-emtansine, UVB1 displayed anti-proliferative actions under 2D and 3D culture conditions. It inhibited both formation and growth of established organoids. In addition, a direct correlation between UVB1 antitumor effects and VDR expression in PDXs was found. In conclusion, all the results reinforce the potential use of these vitamin D analogues as antitumor agents to treat HER2-positive and Triple Negative BC.
Collapse
|
19
|
Alongi F, Nicosia L, Figlia V, Giaj-Levra N, Cuccia F, Mazzola R, Ricchetti F, Rigo M, Vitale C, De Simone A, Naccarato S, Sicignano G, Gurrera D, Corradini S, Ruggeri R. Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique. Clin Transl Oncol 2021; 23:1561-1570. [PMID: 33570720 DOI: 10.1007/s12094-020-02550-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 12/28/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE Radiosurgery (SRS) is an effective treatment option for brain metastases (BMs). Long-term results of the first worldwide experience with a mono-isocentric, non-coplanar, linac-based stereotactic technique in the treatment of multiple BMs are reported. METHODS patients with multiple BMs, life expectancy > 3 months, and good performance status (≤ 2) were treated with simultaneous SRS with volumetric modulated arc technique. Data were retrospectively evaluated. RESULTS 172 patients accounting for 1079 BMs were treated at our institution from 2017 to 2020. The median number of treated metastases was 4 (range 2-22). Primary tumor histology was: lung (44.8%), breast (32%), and melanoma (9.4%). The 2-year LPFS was 71.6%, respectively. A biological effective dose (BED) ≥ 51.3 Gy10 correlated with higher local control. Uncontrolled systemic disease and melanoma histology were independent prognostic factors correlated with decreased iPFS. Patients with > 10 BMs had a trend towards shorter iPFS (p = 0.055). 31 patients received multiple SRS courses (2-7) in case of intracranial progression. The median iOS was 22.4 months. Brainstem metastases and total PTV > 7.1 cc correlated with shorter iOS. The 1- and 2-year WBRT-free survival was 83.2% and 61.1%, respectively. CONCLUSION Long-term results in a large patient population treated with a mono-isocentric, dedicated technique demonstrated its effectiveness and safety also in the case of multiple courses. The shortened treatment time and the possibility to safely spare healthy brain tissue allows the safe treatment of patients with a large number of metastases and to deliver multiple courses of SRS. In selected cases, the administration of WBRT can be delayed.
Collapse
|
20
|
Mazzola R, Figlia V, Rigo M, Cuccia F, Nicosia L, Giaj-Levra N, Ricchetti F, Vitale C, De Simone A, Sicignano G, Naccarato S, Ruggieri R, Alongi F. Geriatric assessment tools and preliminary patient-reported outcomes in a cohort of elderly patients treated with 1.5T MR-guided and daily adapted abdominal-pelvic SBRT. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)36210-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
21
|
Alongi F, Figlia V, Giaj-Levra N, Cuccia F, Mazzola R, Ricchetti F, Rigo M, Vitale C, Corradini S, Ruggieri R, Nicosia L. Non-Coplanar Mono-Isocenter Stereotactic Radiotherapy For Multiple Brain Metastases From Solid Tumors: Results From The First 1000 Metastases. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Cuccia F, Nicosia L, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Vitale C, Corradini S, Ruggieri R, Alongi F. Linac-based SBRT for local recurrent prostate cancer after previous radiotherapy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)36196-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
23
|
Binello N, Garrasi C, Canale E, Sancipriano V, Audisio K, Nicolì V, Airola C, Nocera L, Vitale C, Perotto M. Building a Covid-19 unit in a state of emergency: a cross-generational working model. Healthcare delivery lessons from the pandemic. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2020; 24:10205-10207. [PMID: 33090429 DOI: 10.26355/eurrev_202010_23242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
24
|
Nielsen BE, Stabile S, Vitale C, Bouzat C. Design, Synthesis, and Functional Evaluation of a Novel Series of Phosphonate-Functionalized 1,2,3-Triazoles as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors. ACS Chem Neurosci 2020; 11:2688-2704. [PMID: 32786318 DOI: 10.1021/acschemneuro.0c00348] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The α7 nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel widely distributed in the central nervous system, mainly in the hippocampus and cortex. The enhancement of its activity by positive allosteric modulators (PAMs) is a promising therapeutic strategy for cognitive deficits and neurodegenerative disorders. With the aim of developing novel scaffolds with PAM activity, we designed and synthesized a series of phosphonate-functionalized 1,4-disubstituted 1,2,3-triazoles using supported copper nanoparticles as the cycloaddition reaction catalyst and evaluated their activity on α7 receptors by single-channel and whole-cell recordings. We identified several triazole derivatives that displayed PAM activity, with the compound functionalized with the methyl phosphonate group being the most efficacious one. At the macroscopic level, α7 potentiation was evidenced as an increase of the maximal currents elicited by acetylcholine with minimal effects on desensitization, recapitulating the actions of type I PAMs. At the single-channel level, the active compounds did not affect channel amplitude but significantly increased the duration of channel openings and activation episodes. By using chimeric and mutant α7 receptors, we demonstrated that the new α7 PAMs share transmembrane structural determinants of potentiation with other chemically nonrelated PAMs. To gain further insight into the chemical basis of potentiation, we applied structure-activity relationship strategies involving modification of the chain length, inversion of substituent positions in the triazole ring, and changes in the aromatic nucleus. Our findings revealed that the phosphonate-functionalized 1,4-disubstituted 1,2,3-triazole is a novel pharmacophore for the development of therapeutic agents for neurological and neurodegenerative disorders associated with cholinergic dysfunction.
Collapse
|
25
|
Nicosia L, Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Vitale C, Livi L, Magrini S, Salgarello M, Alongi F. 678P Metastasis-directed stereotactic body radiotherapy (SBRT)-guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration sensitive oligorecurrent prostate cancer: A comparative effectiveness analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|